- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Fresno, California • Northridge, California • Miami, Florida + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 184
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 13 Years to 25 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- novolog insulin, levemir insulin, placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Paul, Minnesota
- Conditions
- Diabetes type1, Obesity
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Schizophrenia
- Interventions
- Insulin or Placebo
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Post-operative Cognitive Decline, Post-operative Delirium
- Interventions
- Aspart insulin, Normal saline, Intranasal mucosal atomizer device
- Drug · Device
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Diabetes Mellitus, Adult Onset
- Interventions
- Cinnamon or placebo 500 mg capsule twice daily
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Type 1 Diabetes
- Interventions
- Insulin Degludec, Insulin Glargine, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes
- Interventions
- Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, Placebo
- Drug
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
- Drug
- Lead sponsor
- Oramed, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Flint, Michigan
- Conditions
- Coronary Artery Disease
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- Metformin, Placebo, mHealth Intervention, Usual Care
- Drug · Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Nashvile, Tennessee
- Conditions
- Diabetes
- Interventions
- Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type II Diabetes
- Interventions
- Farxiga, Placebo, Metformin, Insulin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
- Conditions
- Femoral Shaft Fracture, Tibial Shaft Fracture
- Interventions
- GIK solution, Isotonic Normal Saline Solution
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- Insulin, Placebo, intranasal nebulizer-like device
- Drug · Other · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
- Interventions
- Placebo, AMG 479, AMG 655
- Other · Drug
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 44
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 37 more
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Canakinumab 150 mg, Placebo to Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 70
- States / cities
- Little Rock, Arkansas • Concord, California • Encino, California + 60 more
- Conditions
- HIV Infections, Lipodystrophy, Hyperinsulinemia
- Interventions
- Metformin hydrochloride, Rosiglitazone maleate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
- Conditions
- Obesity
- Interventions
- Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Insulin Resistance
- Interventions
- MICARDIS® (telmisartan)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Westlake Village, California + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- TAK-875, Glimepiride, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more